Emergent BioSolutions manufactures a portfolio of branded protein therapeutics and contract manufactured products at its Winnipeg, Canada site. In 2019, they transitioned their commercial drug products to Cytiva's gloveless filling platform, the SA25 Aseptic Filling Workcell.
Moderna is using an SA25 Aseptic Filling Workcell from Cytiva at its Norwood, Massachusetts site for both clinical trial supply manufacturing and product development.
Gaining control for gene-edited therapies
Locus Biosciences is taking the fight against antibiotic-resistant bacteria using CRISPR-Cas3 gene-edited therapies. They chose the Microcell™ Vial Filler to gain control over their processes.